All News
Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab
Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated.
Read Article
Urinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Read Article
Effective Treatments for Rheumatoid Arthritis ILD
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Read Article
Kaymakci et al. 49 GCA patients in clinical remission undergoing thoracic aortic surgery. Active aortitis in 82%. Abstr#2557 #ACR23 @RheumNow https://t.co/WQh47LThGD https://t.co/DeORKmjYP7
Richard Conway ( View Tweet)
#ACR23 Abs 2463 data from first 3 pts suggest CD19 CAR-T provides possible drug-free remission and resolution of lung/muscle inflammation in antisynthetase syndrome. https://t.co/7udqkDBgqT @rheumnow https://t.co/LSHcI0HMTM
Dr. Rachel Tate ( View Tweet)
A#2547 #ACR23 @RheumNow
Diff 2 Treat (D2T) AxSpa
D2T: fail 2+ b/tsDMARDs w 2 MoA
Very D2T: failure of Rx in less than 2 yrs
28% D2T, 3.8% Very D2T (Compare to 7-10% D2TRA)
More likely: peripheral, uveitis, higher BASDAI, FM
Very D2T also w IBD, higher CRP, longer dis duration https://t.co/HcIXnDRrIq
Eric Dein ( View Tweet)
*not a cappuccino. The dregs of the coffee pot that the kind lady refused to charge me for.
But jet lag is kicking in hard & so is desperation for any caffeine. If it wasn’t irAE friends @cappelliMD @jeffsparks et al up next, I would go to bed.
#ACR23 must roll on! @RheumNow https://t.co/RdCOZlZMbZ
David Liew drdavidliew ( View Tweet)
Another infusion option for axSpA!
INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA
Efficacious - ASAS40 response sustained thru 52 weeks
Safety profile similar to subq version
@RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Robert B Chao, MD ( View Tweet)
Pregnancies outcomes in vasculitis:
- Higher frequency of spontaneous abortion and preterm delivery
- 12% had pre-eclampsia
- Risk higher in multiparous > nalliparous
- Risk highest in small vessel vasculitis
Rector A, Abst#2425 #ACR23 #ACRBest @RheumNow https://t.co/TgbRWw9il5
Dr. Antoni Chan ( View Tweet)
Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN
Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators
#ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33
Janet Pope ( View Tweet)
Body mass is associated w/ ttmt response in RA
Data from RACAT & TEAR studies
TNFi > triple th in underweight gpe but not in overweight gpe
Similar result in gpe w/ low leptin levels
& low adipokine scores
True biology or confounding bias?
@RheumNow #ACR23 ABST2541 https://t.co/OhKj6QNaSa
Aurelie Najm ( View Tweet)
Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better response to TNFi, overweight/obese respond equally to both. Abstr#2541 #ACR23 @RheumNow https://t.co/SROD3esMCD https://t.co/ni3I8tD7wI
Richard Conway ( View Tweet)
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux?
Antibody titres better when not getting regular ritux around boosters
Maybe boosters 9mo (or so) gap after ritux helps immunogenicity
@TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
David Liew drdavidliew ( View Tweet)
The Lupus APOL1 Story
Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
Dr. John Cush RheumNow ( View Tweet)
ROMO vs DEN.
Romosozumab was superior to denosumab
(ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk
Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me
Dr. Antoni Chan ( View Tweet)
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Janet Pope ( View Tweet)
Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly.
Gene expression signatures might tell us more - one key cluster here was 21x predictive.
#ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC
David Liew drdavidliew ( View Tweet)
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Md Yuzaiful Md Yusof ( View Tweet)
During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations.
⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM
➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
HCQ and risk of retinopathy 👁️
DoD database HCQ 44000+ females & 10000+ males
Risk retinopathy HR 1.5
Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7
No adjustment on HCQ dose
@RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Aurelie Najm ( View Tweet)